imetelstat: Clinical Trials

2 trials of imetelstat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 2
Phase 21Active not recruiting 1

Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Imetelstat, Best Available Therapy (BAT) - Myelofibrosis
Phase 3Active not recruitingGeron Corporation3272021-04-122026-07-08
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Imetelstat Sodium, Placebo - Myelodysplastic Syndromes
Phase 2 / Phase 3Active not recruitingGeron Corporation2892016-01-122026-07-17

Conditions studied

Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Polycythemia (1)  ·  Primary Myelofibrosis (1)  ·  Recurrence (1)  ·  Thrombocytosis (1)

Sponsors

Geron Corporation (2)

Countries

Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  Spain (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)

Top investigators

Joe Eid (1)  ·  Tymara Berry, MD (1)

Results publications

PMID 33108243, PMID 35510486, PMID 38048786, PMID 41135032, PMID 41568521

NIH funding

2015 (1), 2023 (1)